follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Actavis shareholders approve Warner Chilcott acquisition proposals

By

Back to Top Comments Print

Parsippany-based specialty pharmaceutical company Actavis announced today its shareholders have approved several proposals related to the company's acquisition of Warner Chilcott. The approvals were required under closing conditions for the acquisition, which is expected to close early in the fourth quarter.

The acquisition, first announced in May, consists of a $5 billion stock swap of 0.16 of an Actavis share for each Chilcott share, valuing the Chilcott shares at $20.08 each. Current Actavis leadership will oversee the resulting company, Actavis PLC.

 

 

 

 

 

Write to the Editorial Department at editorial@njbiz.com

advertisement

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top